Ainos, Inc. announced the granting of a pivotal invention patent in Japan (Patent No. 7619659) for its oral interferon formulation, VELDONA. This patent specifically covers the use of VELDONA to treat and prevent coronavirus infections. This marks a significant breakthrough in antiviral innovation for the company.
The approval positions VELDONA with global potential in the substantial coronavirus market, which is valued at $16 billion. This patent strengthens Ainos' intellectual property portfolio and expands the potential applications of its VELDONA platform beyond its current focus areas. The technology combines unmatched advantages, offering a novel approach to combating viral infections.
Securing this patent in Japan, a key pharmaceutical market, enhances the commercial viability and strategic value of VELDONA. It provides Ainos with a competitive edge in developing therapies for infectious diseases. This achievement underscores the company's commitment to advancing its therapeutic pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.